Results 21 to 30 of about 24,853 (244)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Journal of Hematology & Oncology, 2017
Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor,
Srdan Verstovsek, Jason Gotlib, Ruben A. Mesa, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, Claire N. Harrison, Ronald Paquette, William Sun, Ahmad Naim, Peter Langmuir, Tuochuan Dong, Prashanth Gopalakrishna, Vikas Gupta   +13 more
doaj   +1 more source

Ruxolitinib for myelofibrosis

Experimental and Therapeutic Medicine, 2013
The aim of the present study was to assess the beneficial and harmful effects of ruxolitinib in patients with myelofibrosis (MF). The Cochrane databases, PubMed and Embase were searched for studies published up to October 2012. Randomised controlled trials assessing ruxolitinib versus a placebo or the best available therapy in patients with MF were ...
GU, LIAN, SU, LI, CHEN, QING, XIE, JUANJUAN, WU, GUANGLIANG, YAN, YAN, LIANG, BAOYUN, TAN, JINJING, TANG, NONG   +8 more
openaire   +3 more sources

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis

Hematology, 2022
Objectives Myelofibrosis is a rare bone marrow disorder associated with a high symptom burden, poor prognosis, and shortened survival. While allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofibrosis, the ...
Timothy Devos, Dominik Selleslag, Nikki Granacher, Violaine Havelange, Fleur Samantha Benghiat   +4 more
doaj   +1 more source

Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms

Haematologica, 2019
Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity.
Alicia Arenas Cortés, Rosa Ayala Diaz, Pilar Hernández-Campo, Julián Gorrochategui, Daniel Primo, Alicia Robles, María Luz Morales, Joan Ballesteros, Inmaculada Rapado, Miguel Gallardo, María Linares, Joaquín Martínez-López   +11 more
doaj   +1 more source

Trends in overall mortality among US veterans with primary myelofibrosis

BMC Cancer, 2023
Background Primary myelofibrosis [PMF] is a myeloproliferative neoplasm associated with reduced overall survival (OS). Management strategies for PMF have evolved over the last two decades, including approval of ruxolitinib as the first Janus kinase 1 ...
Tsewang Tashi, Jingbo Yu, Shivani Pandya, Christopher Dieyi, Robyn Scherber, Shreekant Parasuraman   +5 more
doaj   +1 more source

Comparative Analysis of Myelofibrosis Treatment Outcomes with the Use of Ruxolitinib Versus Ruxolitinib with Subsequent Allogeneic Hematopoietic Stem Cell Transplantation

Клиническая онкогематология, 2021
Aim. To comparatively analyze myelofibrosis treatment outcomes with the use of ruxolitinib versus ruxolitinib with subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as to assess the efficacy of ruxolitinib in pre- and post-
Mariya Vladimirovna Barabanshchikova, E. V. Morozova, Yu. Yu. Vlasova, T. L. Gindina, A. V. Evdokimov, I. M. Barkhatov, V. V. Baikov, I. O. Ivanova, T. A. Rudakova, E. A. Bakin, I. S. Moiseev, A. D. Kulagin   +11 more
doaj   +1 more source

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Journal of Allergy and Clinical Immunology, 2020
Background Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation. Objective This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease ...
Yang Cao, Jia-Ming Wei, Liang Zou, Tie-bin Jiang, Gaoxiang Wang, Liting Chen, Liang Huang, Fankai Meng, Lifang Huang, Na Wang, Xiaoxi Zhou, Hui Luo, Zekai Mao, Xing Chen, Jungang Xie, Jing Liu, Hui Cheng, Jianping Zhao, Gang Huang, Wei Wang, Jianfeng Zhou   +20 more
semanticscholar   +1 more source

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Journal of Hematology & Oncology, 2017
Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark Jones, Deanna Kornacki, Kang Sun, Hagop Kantarjian, for the COMFORT-I investigators   +21 more
doaj   +1 more source

COVID-19 in a patient with SISTEMIC sclerosis: The role of ruxolitinib

European Journal of Inflammation, 2021
We describe the case of a 78-year-old Italian woman with COVID-19 affected by Systemic Sclerosis with pulmonary fibrosis treated with Ruxolitinib (Ruxolitinib was provided free of charge by Novartis International AG).
Claudio Ucciferri, Antonio Auricchio, Stefano Marinari, Jacopo Vecchiet, Katia Falasca   +4 more
doaj   +1 more source

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Cancer Medicine, 2019
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease‐related symptoms in patients with myelofibrosis (MF).
Novella Pugliese, Claudia Giordano, Davide Nappi, Luigiana Luciano, Claudio Cerchione, Mario Annunziata, Beniamino Casale, Elena Crisà, Maria Rosaria Villa, Luca Pezzullo, Maria Iovine, Marco Picardi, Francesco Grimaldi, Fabrizio Pane, Vincenzo Martinelli   +14 more
doaj   +1 more source